Last reviewed · How we verify
FUZEON [enfuvirtide]
Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion.
Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion. Used for HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
At a glance
| Generic name | FUZEON [enfuvirtide] |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | HIV fusion inhibitor |
| Target | gp41 (HIV envelope glycoprotein) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Enfuvirtide is a fusion inhibitor that binds to the HR1 region of gp41, an envelope glycoprotein essential for HIV entry. By blocking the conformational changes required for viral-cell membrane fusion, it prevents the virus from entering and infecting CD4+ T lymphocytes. This is the first FDA-approved HIV entry inhibitor and represents a distinct mechanism from reverse transcriptase and protease inhibitors.
Approved indications
- HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
Common side effects
- Injection site reactions (pain, erythema, induration, nodules)
- Hypersensitivity reactions
- Pneumonia
- Diarrhea
- Nausea
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FUZEON [enfuvirtide] CI brief — competitive landscape report
- FUZEON [enfuvirtide] updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI